https://www.marketscreener.com/quote/stock/GSK-PLC-9590199/news/GSK-s-RSV-vaccine-Arexvy-accepted-under-Priority-Review-in-US-for-the-prevention-of-RSV-disease-in-45892159/?utm_source=telegram&utm_medium=social&utm_campaign=share